Charles Schwab Investment Management Inc Galectin Therapeutics Inc Transaction History

Charles Schwab Investment Management Inc

$601 Billion
Q3 2025

A detailed history of Charles Schwab Investment Management Inc transactions in Galectin Therapeutics Inc stock. As of the latest transaction made, Charles Schwab Investment Management Inc holds 44,989 shares of GALT stock, worth $247,439. This represents 0.0% of its overall portfolio holdings.

Number of Shares

44,989

Holding current value

$247,439

% of portfolio

0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	BUY	$2.09 - $5.37 $94,027 - $241,590	44,989 New	44,989 $188,000
Q1 2025 Sep 15, 2025	BUY	$1.1 - $1.76 $25,204 - $40,326	22,913 New	22,913 $27,000
Q1 2025 May 09, 2025	SELL	$1.1 - $1.76 $46,376 - $74,201	-42,160 Reduced 64.79%	22,913 $27,000
Q2 2024 Aug 12, 2024	BUY	$2.13 - $4.2 $101,515 - $200,172	47,660 Added 273.7%	65,073 $147,000
Q2 2021 Aug 16, 2021	SELL	$2.07 - $5.1 $124,355 - $306,382	-60,075 Reduced 77.53%	17,413 $56,000

Q1 2021 May 17, 2021	SELL	$1.96 - $2.57 $15,705 - $20,593	-8,013 Reduced 9.37%	77,488 $169,000
Q3 2020 Nov 13, 2020	SELL	$2.53 - $3.64 $18,818 - $27,074	-7,438 Reduced 8.0%	85,501 $229,000
Q2 2020 Aug 14, 2020	BUY	$1.66 - $3.15 $821 - $1,559	495 Added 0.54%	92,939 $285,000
Q3 2019 Nov 08, 2019	BUY	$3.0 - $4.05 $52,056 - $70,275	17,352 Added 23.11%	92,444 $340,000
Q2 2019 Aug 09, 2019	BUY	$3.61 - $5.0 $271,082 - $375,460	75,092 New	75,092 $312,000
Q2 2018 Aug 08, 2018	SELL	$3.16 - $9.16 $67,624 - $196,024	-21,400 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$1.67 - $2.3 $35,738 - $49,219	21,400	21,400 $46,000

Others Institutions Holding GALT

# of Institutions

Shares Held

11.1M

Call Options Held

142K

Put Options Held

81.4K

View Full List

About GALECTIN THERAPEUTICS INC

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $327M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

More about GALT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

News

Stay updated on Charles Schwab Investment Management Inc with notifications on news.

Account

Charles Schwab Investment Management Inc Galectin Therapeutics Inc Transaction History